drugset / Trial / NCT00005896

Phase I Pilot Study of CD34 Enriched, Fanconi's Anemia Complementation Group C Gene Transduced Autologous Peripheral Blood Stem Cell Transplantation in Patients With Fanconi's Anemia

NCT00005896 ↗

Phase 1 Unknown 6 enrolled University of Minnesota
Treatment

Summary

OBJECTIVES: I. Determine the safety of transferring the Fanconi anemia complementation group C (FACC) gene to hematopoietic progenitors by retroviral mediated gene transfer in patients with Fanconi's anemia, complementation group C. II. Determine the extent of engraftment following this treatment regimen without prior ablation of recipient marrow in these patients. III. Determine the ability of this treatment regimen to correct the cell phenotype and improve hematopoietic function in these patients.

Timeline

Start
2000-03
Primary completion
—
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject Autologous stem cells transduced with FACC retroviral vector Cell therapy — Intravenous
Background filgrastim Protein / enzyme biologic — Subcutaneous

Indications